Alnylam expands management team as it plans for commercialization

US RNAI therapeutics specialist Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced two key appointments to its senior leadership team, expanding the breadth of talent and experience as the company prepares for commercialization of its pipeline and global expansion.

Dr Yvonne Greenstreet has joined as executive vice president, chief operating officer, and Dr Emmanuel Dulac as senior vice president, chief commercial officer. Both Drs Greenstreet and Dulac offer decades of life science experience in drug development and successfully launching medicines to the market in areas of unmet needs. In addition, both have worked in global capacities and have supported execution on strategies involving substantial organizational growth. Barry Greene will continue to serve as the company’s President.

"With our rapid pipeline growth and maturity toward commercial stages, we're focused on building our team to achieve our Alnylam 2020 goals. In this regard, the appointments of Yvonne and Emmanuel significantly bolster the depth of product experience and commercial expertise in our growing organization," said John Maraganore, chief executive of Alnylam. "I'm confident that their insight and leadership will help us realize our mission of building a top-tier biopharmaceutical company founded on RNAi and speed the path of bringing potentially life changing new therapies to patients through innovative drug development, commercial, and patient access strategies," he added.